Clinical Trial Update: Safety and Tolerability Study of V501 in Japanese Boys (V501-200) [Phase 3]

View source ↗

Summary

Phase 3 safety and tolerability trial of V501 in Japanese boys with anogenital HPV infection (condyloma acuminata) completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anogenital Human Papillomavirus Infection
• Condyloma Acuminata

Drugs mentioned

• V501 (HPV vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Anogenital Human Papilloma Virus Infection, Condyloma Acuminata | Phase 3 | Status: COMPLETED | Results posted: 2019-09-06